The Jackson Laboratory (JAX), a global leader in genetics and genomic medicine, announced the completion of its acquisition of the New York Stem Cell Foundation (NYSCF), a pioneering nonprofit focused on advancing cures through stem cell science. The unification creates one of the most comprehensive nonprofit platforms for biomedical discovery, merging JAX’s world-class expertise in genetics and preclinical modeling with NYSCF’s advanced capabilities in stem cell automation and high-throughput research.
Together, the two organizations aim to redefine the landscape of early-stage biomedical research by combining genomics, stem cell innovation, and artificial intelligence. This integrated platform will provide scientists worldwide with more predictive and scalable tools to study disease mechanisms earlier and accelerate the translation of promising discoveries into precision therapies for conditions such as Alzheimer’s, cancer, diabetes, Parkinson’s, and rare diseases.
NYSCF’s Global Stem Cell Array will now complement JAX’s decades-long leadership in mouse genetics and physiological modeling. This state-of-the-art robotic platform enables large-scale, reproducible stem cell experimentation. This technology allows scientists to model disease biology at the level of individual patients, offering unprecedented insights into how genetic and environmental factors drive disease progression and therapeutic response. When combined with the organization’s shared strengths in biomedical data science and AI, the result is a powerful discovery engine for translational medicine.
Founded in 2005, NYSCF has been instrumental in developing scalable stem cell research technologies and advancing regenerative medicine worldwide. By joining forces with JAX, the organization strengthens its ability to drive collaboration, reproducibility, and innovation across the biomedical research ecosystem. The unified entity will operate as a nonprofit organization, maintaining NYSCF’s presence in New York while expanding JAX’s global research network across campuses in Maine, Connecticut, California, Florida, and Japan.
This merger represents a pivotal moment for the life sciences sector—bridging model organism research with human cellular biology to create a more efficient, data-driven pipeline for drug discovery. It aligns with JAX’s mission to empower the biomedical community through open access to advanced tools, datasets, and expertise, driving measurable progress in precision medicine.
KEY QUOTES:
“Bringing JAX and NYSCF together marks a turning point for biomedical research. By combining three powerful approaches – genomics, stem cell innovation, and data-driven AI – we are creating a platform that accelerates discovery from the very start of research and giving scientists stronger tools to turn early insights into breakthroughs for patients.”
Lon Cardon, President and CEO of The Jackson Laboratory
“From the beginning, NYSCF has been driven by the urgency to get cures to patients. Joining with JAX powers that urgency with an even stronger scientific engine. Together, we can move discoveries forward earlier and with greater precision, reducing the costly failures that too often derail later-stage clinical trials.”
Daniel Paull, Vice President of Discovery and Platform Development at The Jackson Laboratory (formerly of NYSCF)
